Drug Profile
Research programme: basal insulin - Nektar Therapeutics
Alternative Names: NKTR-203Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 12 Apr 2011 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
- 31 Dec 2006 Preclinical trials in Diabetes mellitus in USA (unspecified route)